Fauci says Johnson & Johnson COVID-19 vaccine may get approval in two weeks

By Eileen AJ Connelly

Fauci said the US government was working with different companies on six vaccine candidates, two of which have already gotten the go-ahead for use on an emergency basis, one from Pfizer and the other from Moderna

The first single-dose COVID-19 vaccine could get emergency approval in just two weeks, Dr. Anthony Fauci said late Friday.

“I would be surprised if it was any more than two weeks from now that the data will be analyzed and decisions would be made” about the vaccine being developed by New Jersey-based Johnson & Johnson, Fauci said during an appearance on “The Rachel Maddow Show.”

“We’ll look at the data and determine if it’s ready to be given to the public,” Fauci said, “so they can go to the FDA to ask if they can get an emergency use authorization.”

Fauci said the US government was working with different companies on six vaccine candidates, two of which have already gotten the go-ahead for use on an emergency basis, one from Pfizer PFE, +0.19% and the other from Moderna MRNA, -1.47%. These two both require cold storage and two doses.

The J&J JNJ, +1.13% vaccine doesn’t have the same need to be kept super-cold, Fauci said, and only requires one dose. Those factors will make a big difference in the ability to get the shots to people, he said. “It gives a wider range of flexibility,” he said.

Johnson & Johnson has said it expects to have 100 million doses available by April.

Any additional vaccines made available will be a boost for the city and state, which are running out of doses as New Yorkers scramble for vaccination appointments. Mayor Bill de Blasio wrote a letter Friday to President Joe Biden pleading for more vaccine shipments.

This article was first published on NYPost.com

Categories: Vaccine

2 replies

  1. Johnson & Johnson (JNJ) expects to release its COVID-19 vaccine data soon, which could result in an emergency use authorization before the end of February.

    Chief executive officer Alex Gorsky on an earnings call Tuesday said the data is expected to be released “early next week,” boosting optimism for the company whose vaccine could be a game changer.

    The single-shot vaccine would cost no more than $10, a significant discount compared to the two-dose vaccines currently on the market. The vaccine does not require ultra-cold or frozen temperatures for storage and is easier to administer. The news is also welcome as vaccine supplies remain strained amid unprecedented demand.

    https://finance.yahoo.com/news/coronavirus-update-jj-to-release-vaccine-data-next-week-strain-from-brazil-confirmed-in-us-183501020.html

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.